|
業務類別
|
Biotechnology |
|
業務概覽
|
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States. |
| 公司地址
| 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540 |
| 電話號碼
| +1 646 768-9780 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.urogen.com |
| 員工數量
| 291 |
| Mr. Christopher Degnan |
Chief Financial Officer and Principal Accounting Officer |
美元 115.53K |
02/03/2026 |
| Dr. Mark P. Schoenberg, M.D. |
Chief Medical Officer |
-- |
15/07/2025 |
| Ms. Elizabeth Barrett |
Director, President and Chief Executive Officer |
美元 826.01K |
02/03/2026 |
| Mr. Jason Drew Smith |
General Counsel, Chief Compliance Officer and Corporate Secretary |
美元 475.00K |
15/07/2025 |
|
|
| Dr. Arie S. Belldegrun, F.A.C.S.,M.D. |
Chairman of the Board |
02/03/2026 |
| Ms. Cynthia M. Butitta |
Independent Director |
02/03/2026 |
| Mr. Daniel George Wildman |
Independent Director |
02/03/2026 |
| Dr. Leana S. Wen, M. Sc.,M.D. |
Independent Director |
02/03/2026 |
| Dr. Stuart Holden, M.D. |
Independent Director |
02/03/2026 |
| Mr. James A. Robinson, Jr |
Independent Director |
02/03/2026 |
| Ms. Elizabeth Barrett |
Director, President and Chief Executive Officer |
02/03/2026 |
|
|
|
|
